Processing of chemically modified cellulosic fibres

Information

  • Patent Grant
  • 11286601
  • Patent Number
    11,286,601
  • Date Filed
    Monday, March 2, 2020
    4 years ago
  • Date Issued
    Tuesday, March 29, 2022
    2 years ago
Abstract
A chemically modified cellulosic fibre or filament having a moisture content of at least 7% by weight obtained by a process comprising the steps of (i) obtaining cellulosic fibres or filament and chemically modifying the cellulose by substitution to increase its absorbency; (ii) washing the fibres after step (i) in a mixture comprising water and up to 99% by weight of water-miscible organic solvent; (iii) drying the fibres to a moisture content of at least 7% by weight.
Description

This invention relates to chemically modified cellulosic fibres and processes for making nonwoven fibre webs from them. In particular it relates to chemically modified cellulosic fibres which may be carded on a carding machine to produce a web. The fibres may be ultimately processed into nonwoven fabrics for instance by needling or entangling the web, the fabrics being suitable for use in absorbent personal products or absorbent medical products such as wound dressings. Also described are carding processes suitable for forming webs of chemically modified cellulosic fibres or blends of chemically modified fibres with other non-gelling fibres, for example viscose or Tencel or other cellulosic fibres.


Absorbent cellulosic fibres are well known. For instance GB-A-2220881 and GB-A-2094802 describe the production of carboxymethyl cellulose fibres from regenerated cellulose fibres (viscose rayon) fibres or from cotton. Itis also known that carboxymethyl cellulose fibre of greater absorbency and strength can be produced from solvent-spun cellulose fibre. Such fibres are described in EP 0616650 and are manufactured by reacting solvent spun cellulose fibre with a strong alkali and a monochloroacetic acid reagent. It is also known that alternative chemical modification of cellulose fibres is possible and also has the effect of increasing the absorbency of the cellulose fibre. The cellulose fibre can for instance be modified by sulphonation, for example by substitution with an alkyl sulphonate at one or more of the hydroxyl groups on the anhydroglucose monomers that make up the cellulose backbone forming ether linkages. Modified cellulose of this type is known as cellulose sulphonate or cellulose alkyl sulphonate some of the insoluble forms of which are described in WO2012/061225.


Modifying the cellulose fibre requires the fibre to be exposed to one or more reagents which modify the cellulose by substitution, the degree of substitution determining the absorbency and solubility of the fibre. As the degree of substitution is increased the modified cellulose becomes increasingly soluble. As the solubility increases, absorbency also increases.


For some applications, for instance for absorbent gelling wound dressings, the chemically modified fibres need to be insoluble and retain some of their fibrous form when exposed to wound fluid and consequently a balance needs to be found between solubility and absorbency. The chemically modified fibre can be in the form of a tow, filament, sliver, yarn or staple fibre, woven, non-woven or knitted fabric.


Once the modification and neutralisation in acid has taken place, the fibres need to be washed to remove any unreacted alkali, chloroacetate, alkylsulphonate, other modifying agent or any by-products such as sodium chloride or sodium glycollate. An aqueous wash is generally used initially, preferably a mixture of water with a water-miscible organic solvent such as water and IMS, the major portion of the wash being organic solvent. The wash may contain an organic hydroxyl compound, a surfactant, and/or acid. The organic hydroxyl compound is a compound containing at least one alcoholic hydroxyl group, for example ethanol, methanol or another low molecular weight alcohol and/or a compound such as ethylene glycol or propylene glycol.


The final wash or finish typically comprises a large percentage of alcohol for instance, 99% industrial alcohol and 1% emulsifier or 100% alcohol. After washing, the fibres are dried at low temperature for instance as described in EP 0680344, by forced air drying or radiant heat drying.


As the washing step or steps to which the fibres are subjected following modification involve the use of relatively high percentages of organic solvents such as industrial alcohol, the drying of the fibres requires the solvents that are released to be managed from an environmental and safety perspective. It would be desirable to reduce the percentage of organic solvents used in the washing process so that environmental and safety standards can be readily met. There are also potential cost and efficiency advantages to using a lower percentage of organic solvents as the cost of materials and duty are reduced.


We have found that reducing, for instance, the percentage of organic solvent in the wash liquor used to wash modified cellulose fibres results in fibres that have a lower tensile strength making them less suitable for processing on textile machinery such as a carding machine. The lower tensile strength can lead to the problem of fibre breakage on carding which gives higher levels of airborne lint or dust (fly) and greater shedding of broken fibre from the finished fabric. The higher level of fly necessitates increased cleaning and environment management in the fabric production process which in turn increases cost. There is also more wastage in the process as fibres tend to drop out of the fabric during the process of manufacture.


Fibre breakage can also adversely affect the staple length which has the effect of reducing the strength of a carded web and nonwoven fabric made from the fibres. It is possible that fibre breakage leads to a failed card process where no non-woven mat is produced. A weaker product can be more difficult to remove from the wound as the integrity of the dressing can be compromised.


We have now found that it is possible to mitigate the problem of low tensile strength in modified fibres by controlled management of the moisture content of the fibres.


Accordingly the invention provides a chemically modified cellulosic web of fibres having a tensile strength of at least 3N per cm (N/cm) in the cross direction produced by processing fibres having a moisture content of at least 7% by weight.


Controlling the moisture content of the fibres, either by controlling the drying process following washing of the modified fibres as part of the chemical modification process or by conditioning the fibres to increase their moisture content to at least 7% subsequent to drying, increases the tensile strength of the fibres to the point where it is possible to process the fibres for example on a carding machine to produce a non-woven fibre web without the production of excessive fly or shedding from a fabric produced from the web. Preferably the moisture content of the fibres is kept at between 11 and 20% by controlling the drying process following washing of the modified fibres as part of the chemical modification process.


Preferably the tensile strength is measured in the cross direction on needled webs having a basis weight in the range of 80 to 120 gsm.


Accordingly the invention provides, in a further aspect, a process for producing a non-woven web of chemically modified cellulosic fibres comprising the steps of:

    • (i) obtaining chemically modified cellulosic fibres with a moisture content of at least 79%;
    • (ii) carding the fibres to make a nonwoven web of fibres.


The fibres are typically those resulting from a modification process using a wash or final rinse comprising less than 99% by weight such as 95% by weight of organic solvent in the wash liquor. By controlling the moisture content, the fibres can be processed into a consolidated form that allows a fabric to be produced by conventional carding means while mitigating the problem of fibre breakage and fly in the environment of the fabric production plant. A consolidated form could for example be a yarn, sliver, woven, non-woven or knitted fabric.


When the fibres are to be processed using textiling machinery, if it is found that the moisture content of the fibres is too low, the moisture content of the modified cellulosic fibres is increased by exposing the fibres to a moisture rich environment for at least 24 hours. Alternatively the drying of the fibres at the end of the chemical modification process can be controlled so that the moisture content of the fibres is maintained above 7% until the fibres are subjected to further processing such as with textiling machinery for instance by carding and needling.


Preferably the carded, needled fibre web has a tensile strength of from 3N/cm to 25N/cm, more preferably from 7N/cm to 25N/cm and most preferably from 10N/cm to 25N/cm.


The tensile strength of the carded, needled web is measured by cutting five specimens to a size of 25 mm×75 mm with the long dimension being in the direction to be tested. Tensile testing is carried out at a gauge length (effective test fabric length) of 50 mm. One end of the sample is fixed in an upper jaw of a tensile testing machine and allowed to dangle into the lower jaw. The sample is then fixed by closing the jaws without stretching the sample or allowing it to be slack. The crosshead speed is set to 100 mm/min and the sample pulled to break. The tensile strength is calculated by dividing the force at break by the sample width in cm.


Preferably the moisture content of the fibres prior to processing with textiling machinery is from 7% to 20% by weight and more preferably from 11% to 18%. More preferably the moisture content is from 11.5% and 15% by weight and most preferably it is between 12 and 15% by weight. A moisture content of 12.5% to 15% is particularly preferred and 15% is most preferred.


By the term moisture content is meant the amount of moisture (measured by weight) contained in the sample of fibres as a percentage of its conditioned weight and measured by the loss on drying.


The moisture content of the fibres is measured by calculating the loss on drying using a moisture balance operated in accordance with the instrument manual. For convenience, during the process for making the fibres, comparative measurements of moisture content can be made using a moisture meter for instance an Aquaboy (TEMI).


By the term carding in the present invention is meant a mechanical process that disentangles, cleans and intermixes fibres to produce a continuous web or sliver suitable for further processing.


In a further aspect of the invention, the invention provides a chemically modified cellulosic fibre having a moisture content of at least 7% by weight.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1 shows the fiber moisture content vs. tensile strength of carded needled fabric in the transverse (cross) direction before and after moisture conditioning to increase moisture content.





The invention will now be illustrated by the following examples.


EXAMPLE 1

Comparison of the moisture content of fibres vs their tensile strengths once carded and needled was made by measuring the initial moisture content of dried modified cellulosic fibres produced using washes of varying alcohol content. That initial moisture content was then increased by conditioning the fibres in a moist atmosphere for 24 hours at a relative humidity of 55 to 60% and the tensile strength of the needled fabric measured again.



FIG. 1 shows the fibre moisture content vs tensile strength of carded needled fabric in the transverse (cross) direction before and after moisture conditioning to increase the moisture content.


The results show that the moisture content of the fibres influences the tensile strength of the resulting carded and needled web. The column headed IDA in the table of FIG. 1 refers to the percentage of IDA (industrial denatured alcohols) used in the wash liquor as part of the modification process. The columns headed % refer to the % moisture in the fibre and N/cm to the tensile strength of the resulting carded needled web in the transverse direction. It can be seen from FIG. 1 that decreasing the % of IDA in the wash liquor has a negative influence on tensile strength for carded and needled webs made from unconditioned fibres. It can also be seen that once the moisture content of those fibres is raised to more than 11%, such as 12.5 to 14% moisture those tensile strength values of the carded needled web increase.


EXAMPLE 2

Effect of moisture content on the tensile strength of silver containing wound dressings.


Dressings were prepared by modification of solvent spun cellulose tow to a degree of substitution of 0.3 to form carboxymethylcellulose, neutralising to a pH of 5.5 with an organic acid. Adding 1.2% cationic silver by an ion exchange process in a largely organic solvent such as by the process described in Ep1343510, washing in an aqueous organic solution containing sodium chloride and di-sodium EDTA for light stabilisation and to entrain approximately 0.4% EDTA. Followed by washing in organic solvent wash containing fibre finishing agents including tween 20 and benzethonium chloride (to give 0.135% wt/wt BeCl on the finished product) and subsequently warm air drying, cutting to staple and processing into a nonwoven felt by carding and a needle punching process. The dressings were cut to size from the web and packaged in a light, moisture and vapour impermeable heat sealed foil pouch.


The dressings were removed from the packs and then subjected to various controlled environments.


Controlled Environments

    • Ambient as packed, tested without any preconditioning
    • Zero humidity: Stored in a square desiccator with 3 perforated perspex shelves above a layer of silica gel desiccant, conditioned for a minimum of 5 days
    • 25° C./60% RH, for a minimum of 6 days
    • 30° C./65% RH, for a minimum of 6 days
    • 40° C./75% RH, for a minimum of 6 days


Samples (ambient as packed) were tested immediately after opening the packs. Samples removed from the other environments were sealed into plastic bags during removal, and then tested immediately. The plastic bags (also preconditioned in corresponding controlled environments) were used to maintain the humidity of the environment of the samples until the point of testing.


Loss on Drying CLOD)


LOD of the samples was determined using the Ohaus moisture balance MB23 operated in accordance with the instruction manual. A sample mass of greater than 1 gram was used. Samples were cut to fit within the weighing pan, ensuring there was adequate clearance from the heating element. A standardised method was used with a maximum temperature limit of 110° C. The endpoint was determined automatically when the sample mass stopped reducing and was stable. Under these conditions the fabric did not char. Typically, samples would be subjected to a 10 minute cycle.


Fabric Thickness (Loft)


Samples were tested using the Hampden Soft Materials Thickness Gauge, Model FMTml-4D, S/N 14082. Fabric thickness (sometimes referred to as loft) was determined for 6 dressings per batch.


Fabric Dry Tensile Strength


2.5 cm×7.5 cm rectangular strips were cut from along the length (machine direction) and across the width (transverse direction) using a ribbon cutting die and press. Samples were conditioned as described Table 1. The peak force and the extension at which that force occurred were recorded when a 50 mm test length was stretched at a constant separation rate of 100 mm per minute.


Results








TABLE 1







Relationship between absolute and relative humidity















25° C./
30° C./
40° C./


Conditioning
Dry
Ambient
60% RH
65% RH
75% RH















Moisture
0.00
9.50
13.81
19.71
38.29


(g/m3)







Thickness
0.170
0.190
0.198
0.183
0.202


(mm)







LOD %
9.28
11.93
14.17
15.27
18.10


Tensile
3.10
5.19
5.80
5.36
7.75


Machine







(N/cm)







Tensile
5.15
6.53
11.12
10.23
14.28


Transverse







(N/Cm)







GSM
91
102
105
98
108


(g/m2)









Loss on drying is the summation of all the volatile substances that can be removed by heating at 110° C. These include ethanol, water and to some degree acetic acid.


For this particular fibre, for this example, textile trials have shown that fibres for use in wound dressings according to the invention can be successfully textiled between 42% and 50% RH at around 18 to 20° C. Trials suggest that fibres with 10.5% to 11.5% w/w moisture content can be carded efficiently.


The results show that tensile strength, loft and LOD are all functions of equilibrium moisture content. The results suggest that fibres with a moisture content of greater than 9% will be able to be textiled to produce dressings suitable for use in the present invention.


EXAMPLE 3

Materials


Two gelling fibre types were used in this study; cellulose ethylsulphonate (CES) and carboxymethyl cellulose (CMC).









TABLE 1





Surnmary of gelling fibres used


Gelling Fibre







CES fibre tow


CMC fibre tow









Methods


Single fibres were mounted onto card windows as described in BS EN 5079:1996.


In addition, tow bundles were prepared to assess the moisture content.


Fibres were oven dried at 105° C. for one hour prior to being conditioned at the chosen relative humidity for a minimum of 16 hours. The mass of the oven dried tow bundles (W1) and the conditioned tow bundles (W2) was taken to assess the moisture content of the fibres, using Equation 1.










Moisture





Content






(
%
)


=




W

2

-

W

1



W

2


×
100





Equation





1







Single fibre tensile strength of the conditioned samples was undertaken using the method described in BS EN 5079:1996.


Fibres were tested at 45% RH, 65% RH, and 85% RH.


Results


Results found that a significantly higher (P≤0.05) tensile strength was seen in the samples conditioned at 65% RH than those conditioned at 45% RH and 85% RH as shown in Table 2.









TABLE 2







Summary of results










Relative Humidity of Atmosphere (%) Ambient
45
65
85














CES
Moisture Content in fibre (%) w/w
9
15
22



Mean Fibre Breaking Strength (cN)
4.85
6.16
3.79



Standard Deviation (cN)
1.08
3.61
1.21



T-Test aganst 65% RH data P value
0.016
N/A
0.000


CMC
Moisture Content in fibre (%) w/w
12
15
21



Mean Fibre Breaking Strength (cN)
6.04
3.24
4.16



Standard Deviation (cN)
2.65
6.06
1.55



T-Test against 65% RH data P value
0.029
N/A
0.000








Claims
  • 1. A process for processing a cellulosic fibre or a cellulosic filament, the process comprising: chemically modifying the cellulose of the cellulosic fibre or the cellulosic filament by substitution to increase absorbency;washing the chemically modified cellulosic fibre or chemically modified cellulosic filament in a wash solution comprising up to 99% by weight of an organic solvent and at least 95% by weight of the organic solvent; andadjusting the washed fibre or washed filament to a moisture content of at least 7% by weight.
  • 2. The process of claim 1, wherein the washed fibre or washed filament is dried to a moisture content from 11% to 18% by weight.
  • 3. The process of claim 1, wherein the adjusting step comprises drying the washed fibre or washed filament.
  • 4. The process of claim 3, further comprising carding the dried fibre or dried filament to make a nonwoven web of fibre.
  • 5. The process of claim 4, further comprising needling the nonwoven web of fibre to form a wound dressing.
  • 6. The process of claim 5, further comprising sealing the wound dressing in a pouch that maintains the moisture content of the wound dressing in a sterile environment.
  • 7. The process of claim 1, wherein the adjusting step comprises conditioning the washed fibre or washed filament in an atmosphere having a relative humidity of at least 40%.
  • 8. The process of claim 7, wherein the relative humidity is from 45% to 85%.
  • 9. The process of claim 7, further comprising carding the conditioned fibre or filament to produce a non-woven web of chemically modified cellulosic fibre.
  • 10. A process for producing a non-woven web of chemically modified cellulosic fibres, the process comprising: neutralizing chemically modified cellulosic fibres;finishing the chemically modified cellulosic fibres with a solution comprising less than 99% by weight of an organic solvent to produce finished chemically modified cellulosic fibres;adjusting the moisture content of the finished chemically modified cellulosic fibres to a moisture content from 11% to 20% by weight;processing the finished chemically modified cellulosic fibres into the non-woven web of chemically modified cellulosic fibres, and wherein the moisture content of the non-woven web of chemically modified cellulosic fibres is from 11% to 20% by weight; andpackaging the non-woven web of chemically modified cellulosic fibres in a pouch that maintains the moisture content of the non-woven web of chemically modified cellulosic fibres in a sterile environment, and wherein the packaged non-woven web of chemically modified cellulosic fibres has a tensile strength of at least 3N per cm,wherein the solution comprises at least 95% by weight of the organic solvent.
  • 11. The process of claim 10, wherein the solution comprises less than 95% by weight of an organic solvent.
  • 12. The process of claim 10, wherein the adjusting step comprises drying the finished chemically modified cellulosic fibres to achieve the moisture content from 11% to 20% by weight.
  • 13. The process of claim 10, wherein the adjusting step comprises conditioning the finished chemically modified cellulosic fibres in air having a relative humidity of at least 40% to achieve the moisture content from 11% to 20% by weight.
  • 14. The process of claim 13, wherein the relative humidity is from 45% to 85%.
  • 15. The process of claim 10, wherein the adjusting step comprises drying the finished chemically modified cellulosic fibres in air having a relative humidity of at least 40% to achieve the moisture content from 11% to 20% by weight.
  • 16. A non-woven web of chemically modified cellulosic fibres produced by the process of claim 10.
  • 17. The non-woven web of chemically modified cellulosic fibres of claim 16, wherein the non-woven web of chemically modified cellulosic fibres has a tensile strength from 3N/cm to 25N/cm.
  • 18. The non-woven web of chemically modified cellulosic fibres of claim 16, wherein the non-woven web of chemically modified cellulosic fibres has a basis weight from 80 gsm to 120 gsm.
  • 19. The non-woven web of chemically modified cellulosic fibres of claim 16, wherein the tensile strength is in a cross-direction.
Priority Claims (2)
Number Date Country Kind
1223408 Dec 2012 GB national
1308774 May 2013 GB national
CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No. 14/654,498 filed Jun. 19, 2015, which is a U.S. National Phase application of International Patent Application Serial No. PCT/GB2013/053374 filed Dec. 20, 2013, which claims priority to Great Britain Patent Application Serial No. 1223408.4 filed Dec. 20, 2012, and Great Britain Patent Application Serial No. 1308774.7 filed May 15, 2013, the contents of each application are incorporated herein by reference in their entirety.

US Referenced Citations (664)
Number Name Date Kind
2396514 Kreidl et al. Mar 1946 A
2785106 Mendelson Mar 1957 A
3061469 Manowitz et al. Oct 1962 A
3092552 Romans Jun 1963 A
4258056 Lentsch Mar 1981 A
4344324 Langer Aug 1982 A
4612337 Fox, Jr. et al. Sep 1986 A
4655758 Ring et al. Apr 1987 A
4728323 Matson Mar 1988 A
4829129 Kelley May 1989 A
4889654 Mason et al. Dec 1989 A
4906100 Rice et al. Mar 1990 A
4973848 Kolobanov et al. Nov 1990 A
5064652 Bay Nov 1991 A
5326567 Capelli Jul 1994 A
5340924 Tomita et al. Aug 1994 A
5407656 Roozdar Apr 1995 A
5527534 Myhling Jun 1996 A
5567495 Modak et al. Oct 1996 A
5616347 Alliger et al. Apr 1997 A
5662913 Capelli Sep 1997 A
5709870 Yoshimura et al. Jan 1998 A
5731083 Bahia et al. Mar 1998 A
5744151 Capelli Apr 1998 A
5744155 Friedman et al. Apr 1998 A
5762620 Cartmell et al. Jun 1998 A
5820918 Ronan et al. Oct 1998 A
5848995 Walder Dec 1998 A
5860947 Stamler Jan 1999 A
5998488 Shinohara et al. Dec 1999 A
6075177 Bahia Jun 2000 A
6207601 Maurer et al. Mar 2001 B1
6238691 Huang May 2001 B1
6290496 Azar et al. Sep 2001 B1
6413556 Bathurst et al. Jul 2002 B1
6468965 Cutler Oct 2002 B1
6548730 Patel et al. Apr 2003 B1
6555508 Paul et al. Apr 2003 B1
6605751 Gibbins et al. Aug 2003 B1
6669981 Parsons et al. Dec 2003 B2
6750262 Haehnle et al. Jun 2004 B1
6753063 Pung et al. Jun 2004 B1
7033511 Zawada et al. Apr 2006 B2
7267828 Parsons et al. Sep 2007 B2
8637072 Kershaw et al. Jan 2014 B2
9149035 Percival et al. Oct 2015 B2
10016537 Menon et al. Jul 2018 B2
10046096 Askem et al. Aug 2018 B2
10076447 Barta et al. Sep 2018 B2
10076587 Locke et al. Sep 2018 B2
10143784 Walton et al. Dec 2018 B2
10426670 von Blucher et al. Oct 2019 B2
10426747 Johnson Oct 2019 B2
10426874 Chien et al. Oct 2019 B2
10426875 Blott et al. Oct 2019 B2
10426938 Locke et al. Oct 2019 B2
10434015 Taylor et al. Oct 2019 B2
10434142 Niazi et al. Oct 2019 B2
10434210 Olson et al. Oct 2019 B2
10434284 Hanson et al. Oct 2019 B2
10449094 Donda et al. Oct 2019 B2
D866756 Allen et al. Nov 2019 S
10463760 Karthikeyan et al. Nov 2019 B2
10463773 Haggstrom et al. Nov 2019 B2
10470933 Riesinger Nov 2019 B2
10470936 Wohlgemuth et al. Nov 2019 B2
10471122 Shi et al. Nov 2019 B2
10471190 Locke et al. Nov 2019 B2
10478345 Barta et al. Nov 2019 B2
10478346 Knutson Nov 2019 B2
10478394 Yu Nov 2019 B2
10485707 Sexton Nov 2019 B2
10485891 Andrews et al. Nov 2019 B2
10485892 Hands et al. Nov 2019 B2
10485906 Freedman et al. Nov 2019 B2
10486135 Yang et al. Nov 2019 B2
10492956 Zamierowski Dec 2019 B2
10493178 Marchant et al. Dec 2019 B2
10493184 Collinson et al. Dec 2019 B2
10493185 Stokes et al. Dec 2019 B2
10500099 Hung et al. Dec 2019 B2
10500103 Croizat et al. Dec 2019 B2
10500104 Sookraj Dec 2019 B2
10500173 Yang et al. Dec 2019 B2
10500235 Wardell Dec 2019 B2
10500300 Dybe et al. Dec 2019 B2
10500301 Laurensou Dec 2019 B2
10500302 Holm et al. Dec 2019 B2
10501487 Andrews et al. Dec 2019 B2
10506928 Locke et al. Dec 2019 B2
10507141 Allen et al. Dec 2019 B2
10507259 Cree et al. Dec 2019 B2
10512707 Whalen, III et al. Dec 2019 B2
10525170 Havenstrite et al. Jan 2020 B2
10532137 Pratt et al. Jan 2020 B2
10532194 Locke et al. Jan 2020 B2
10537657 Phillips et al. Jan 2020 B2
10542936 Goldberg et al. Jan 2020 B2
10543133 Shaw et al. Jan 2020 B2
10543293 Suschek Jan 2020 B2
10548777 Locke et al. Feb 2020 B2
10549008 Yoo Feb 2020 B2
10549016 Bushko et al. Feb 2020 B2
10549017 Hsiao et al. Feb 2020 B2
10555838 Wu et al. Feb 2020 B2
10555839 Hartwell Feb 2020 B2
10556044 Robinson et al. Feb 2020 B2
10561533 Hoggarth et al. Feb 2020 B2
10561536 Holm et al. Feb 2020 B2
10568767 Addison et al. Feb 2020 B2
10568768 Long et al. Feb 2020 B2
10568770 Robinson et al. Feb 2020 B2
10568771 MacDonald et al. Feb 2020 B2
10568773 Tuck et al. Feb 2020 B2
10568983 Gerdes et al. Feb 2020 B2
10575991 Dunn Mar 2020 B2
10575992 Sarangapani et al. Mar 2020 B2
10576037 Harrell Mar 2020 B2
10576189 Locke et al. Mar 2020 B2
10583042 Sarangapani et al. Mar 2020 B2
10583228 Shuler et al. Mar 2020 B2
10589007 Coulthard et al. Mar 2020 B2
10590184 Kuo Mar 2020 B2
10610414 Hartwell et al. Apr 2020 B2
10610415 Griffey et al. Apr 2020 B2
10610623 Robinson et al. Apr 2020 B2
10617569 Bonn Apr 2020 B2
10617608 Shin et al. Apr 2020 B2
10617769 Huang Apr 2020 B2
10617784 Yu et al. Apr 2020 B2
10617786 Kluge et al. Apr 2020 B2
10618266 Wright et al. Apr 2020 B2
10624984 Courage et al. Apr 2020 B2
10625002 Locke et al. Apr 2020 B2
10632019 Vitaris Apr 2020 B2
10632224 Hardy et al. Apr 2020 B2
10639206 Hu et al. May 2020 B2
10639350 Arber et al. May 2020 B2
10639404 Lichtenstein May 2020 B2
10646614 Grinstaff et al. May 2020 B2
10653562 Robinson et al. May 2020 B2
10653782 Ameer et al. May 2020 B2
10653810 Datt et al. May 2020 B2
10653821 Nichols May 2020 B2
10653823 Bharti et al. May 2020 B2
10660799 Wu et al. May 2020 B2
10660851 Millis et al. May 2020 B2
10660992 Canner et al. May 2020 B2
10660994 Askem et al. May 2020 B2
10667955 Allen et al. Jun 2020 B2
10667956 Van Holten et al. Jun 2020 B2
10682257 Lu Jun 2020 B2
10682258 Manwaring et al. Jun 2020 B2
10682259 Hunt et al. Jun 2020 B2
10682318 Twomey et al. Jun 2020 B2
10682386 Ellis-Behnke et al. Jun 2020 B2
10682446 Askem et al. Jun 2020 B2
10687983 Dahlberg et al. Jun 2020 B2
10687985 Lee et al. Jun 2020 B2
10688215 Munro et al. Jun 2020 B2
10688217 Hanson et al. Jun 2020 B2
RE48117 Albert et al. Jul 2020 E
10702419 Locke et al. Jul 2020 B2
10702420 Hammond et al. Jul 2020 B2
10703942 Tunius Jul 2020 B2
10709760 Gronberg et al. Jul 2020 B2
10709807 Kshirsagar Jul 2020 B2
10709883 Spector Jul 2020 B2
10716711 Locke et al. Jul 2020 B2
10716874 Koyama et al. Jul 2020 B2
10729589 Dorian et al. Aug 2020 B2
10729590 Simmons et al. Aug 2020 B2
10729826 Lin Aug 2020 B2
10736787 Hannigan et al. Aug 2020 B2
10736788 Locke et al. Aug 2020 B2
10736985 Odermatt et al. Aug 2020 B2
10737003 Fujisaki Aug 2020 B2
10743900 Ingram et al. Aug 2020 B2
10744040 Kazala, Jr. et al. Aug 2020 B2
10744041 Hartwell Aug 2020 B2
10744225 Lindgren et al. Aug 2020 B2
10744237 Guidi et al. Aug 2020 B2
10744238 Guidi et al. Aug 2020 B2
10744239 Armstrong et al. Aug 2020 B2
10744240 Simmons et al. Aug 2020 B2
10751212 Raza et al. Aug 2020 B2
10751442 Bonnefin et al. Aug 2020 B2
10751452 Topaz Aug 2020 B2
10758423 Pigg et al. Sep 2020 B2
10758424 Blott et al. Sep 2020 B2
10758425 Blott et al. Sep 2020 B2
10758426 Eddy Sep 2020 B2
10758651 Blott et al. Sep 2020 B2
10765561 Lattimore et al. Sep 2020 B2
10765783 Locke et al. Sep 2020 B2
10772767 Bjork et al. Sep 2020 B2
10772999 Svensby Sep 2020 B2
10779993 Bishop et al. Sep 2020 B2
10780114 Udagawa et al. Sep 2020 B2
10780194 Flach et al. Sep 2020 B2
10780201 Lin Sep 2020 B2
10780202 Askem et al. Sep 2020 B2
10780203 Coulthard et al. Sep 2020 B2
10782238 Hicks et al. Sep 2020 B2
10792191 Robinson et al. Oct 2020 B2
10792192 Tout et al. Oct 2020 B2
10792337 Leung et al. Oct 2020 B2
10792404 Hu et al. Oct 2020 B2
10792482 Randolph et al. Oct 2020 B2
10800905 Delli-Santi et al. Oct 2020 B2
10806819 Shuler Oct 2020 B2
20020091074 Wooley et al. Jul 2002 A1
20020160941 Kruzel Oct 2002 A1
20020172709 Nielsen et al. Nov 2002 A1
20020183808 Biel Dec 2002 A1
20030180345 Hill et al. Sep 2003 A1
20030180346 Woods Sep 2003 A1
20040001880 Bowler et al. Jan 2004 A1
20040247652 Sabesan Dec 2004 A1
20050059731 Albrecht et al. Mar 2005 A1
20060019571 Lange et al. Jan 2006 A1
20060051385 Scholz Mar 2006 A1
20060051430 Arata et al. Mar 2006 A1
20060115440 Arata et al. Jun 2006 A1
20060155260 Blott et al. Jul 2006 A1
20060172000 Cullen et al. Aug 2006 A1
20060234959 Biel et al. Oct 2006 A1
20060254988 Frampton Nov 2006 A1
20070042024 Gladman et al. Feb 2007 A1
20070134136 Polyakov et al. Jun 2007 A1
20070166399 Burton et al. Jul 2007 A1
20070185426 Ambrosio et al. Aug 2007 A1
20070219512 Heaton et al. Sep 2007 A1
20070239078 Jaeb Oct 2007 A1
20070255192 Patel et al. Nov 2007 A1
20080112920 Chia et al. May 2008 A1
20080188558 Godal et al. Aug 2008 A1
20080226724 Ji et al. Sep 2008 A1
20090012440 Bray et al. Jan 2009 A1
20090177135 Rogers et al. Jul 2009 A1
20090234307 Vitaris Sep 2009 A1
20090259203 Hu et al. Oct 2009 A1
20090293887 Wilkes et al. Dec 2009 A1
20090299303 Seegert Dec 2009 A1
20100015208 Kershaw et al. Jan 2010 A1
20100030178 MacMeccan et al. Feb 2010 A1
20100113537 Nonaka May 2010 A1
20100125233 Edward S. et al. May 2010 A1
20100125258 Coulthard et al. May 2010 A1
20100129633 Law May 2010 A1
20100137775 Hu et al. Jun 2010 A1
20100185163 Heagle Jul 2010 A1
20100298790 Guidi et al. Nov 2010 A1
20100310845 Bond et al. Dec 2010 A1
20110015595 Robinson et al. Jan 2011 A1
20110028918 Hartwell Feb 2011 A1
20110112457 Holm et al. May 2011 A1
20110117025 Dacosta et al. May 2011 A1
20110178451 Robinson et al. Jul 2011 A1
20110224593 Tunius Sep 2011 A1
20110224630 Simmons et al. Sep 2011 A1
20110230849 Coulthard et al. Sep 2011 A1
20110237994 Russ et al. Sep 2011 A1
20110251566 Zimnitsky et al. Oct 2011 A1
20110257572 Locke et al. Oct 2011 A1
20110257573 Hong et al. Oct 2011 A1
20110275972 Rosenberg Nov 2011 A1
20110319808 Bowler et al. Dec 2011 A1
20120071845 Hu et al. Mar 2012 A1
20120130332 Cotton et al. May 2012 A1
20120136325 Allen et al. May 2012 A1
20120202398 Marshall et al. Aug 2012 A1
20120209226 Simmons et al. Aug 2012 A1
20120232502 Lowing Sep 2012 A1
20130053795 Coulthard et al. Feb 2013 A1
20130123728 Pratt et al. May 2013 A1
20130226063 Taylor et al. Aug 2013 A1
20140005618 Locke et al. Jan 2014 A1
20140074053 Locke et al. Mar 2014 A1
20140188060 Robinson et al. Jul 2014 A1
20140194838 Wibaux et al. Jul 2014 A1
20140200532 Robinson et al. Jul 2014 A1
20140236112 Von Wolff et al. Aug 2014 A1
20140256925 Catchmark et al. Sep 2014 A1
20140276499 Locke et al. Sep 2014 A1
20140296804 Hicks et al. Oct 2014 A1
20140308338 Nierle et al. Oct 2014 A1
20140309574 Cotton Oct 2014 A1
20150018433 Leipzig et al. Jan 2015 A1
20150057624 Simmons et al. Feb 2015 A1
20150071985 Walker et al. Mar 2015 A1
20150079152 Wuollett et al. Mar 2015 A1
20150094674 Pratt et al. Apr 2015 A1
20150104486 Bonnefin et al. Apr 2015 A1
20150112311 Hammond et al. Apr 2015 A1
20150119831 Robinson et al. Apr 2015 A1
20150119834 Locke et al. Apr 2015 A1
20150141941 Allen et al. May 2015 A1
20150148785 Kleiner May 2015 A1
20150174304 Askem et al. Jun 2015 A1
20150245949 Locke et al. Sep 2015 A1
20150246164 Heaton et al. Sep 2015 A1
20150250979 Loske Sep 2015 A1
20150265741 Duncan et al. Sep 2015 A1
20150265743 Hanson et al. Sep 2015 A1
20150320901 Chandrashekhar-Bhat et al. Nov 2015 A1
20160008293 Shi et al. Jan 2016 A1
20160038626 Locke et al. Feb 2016 A1
20160051724 Sahin et al. Feb 2016 A1
20160067107 Cotton Mar 2016 A1
20160100987 Hartwell et al. Apr 2016 A1
20160101207 Parsons et al. Apr 2016 A1
20160106878 Yang et al. Apr 2016 A1
20160106892 Hartwell Apr 2016 A1
20160166422 Karim et al. Jun 2016 A1
20160193244 Ota et al. Jul 2016 A1
20160222548 Agboh Aug 2016 A1
20160271178 Hauser et al. Sep 2016 A1
20160287743 Andrews Oct 2016 A1
20160339158 Collinson et al. Nov 2016 A1
20160374847 Lachenbruch et al. Dec 2016 A1
20170014275 Schneider Jan 2017 A1
20170049111 Patton et al. Feb 2017 A1
20170072669 Sekido et al. Mar 2017 A1
20170079276 Percival et al. Mar 2017 A1
20170128269 Coulthard et al. May 2017 A1
20170189237 Locke et al. Jul 2017 A1
20170189575 Lee et al. Jul 2017 A1
20170209615 Tornero Garcia et al. Jul 2017 A1
20170232161 Fewkes et al. Aug 2017 A1
20170258956 Flach et al. Sep 2017 A1
20170347661 Parsons Dec 2017 A1
20170367895 Holm et al. Dec 2017 A1
20170368239 Askem et al. Dec 2017 A1
20180008742 Hoggarth et al. Jan 2018 A1
20180014974 Hoggarth et al. Jan 2018 A1
20180023217 Patton et al. Jan 2018 A1
20180030321 Tunius Feb 2018 A1
20180042789 Bradford et al. Feb 2018 A1
20180078423 Magin et al. Mar 2018 A1
20180086903 Zhang et al. Mar 2018 A1
20180118809 Mearns Spragg May 2018 A1
20180133066 Ahsani et al. May 2018 A1
20180140467 Hunt May 2018 A1
20180140822 Robinson et al. May 2018 A1
20180200414 Askem et al. Jul 2018 A1
20180221531 Bender et al. Aug 2018 A1
20180236124 Young et al. Aug 2018 A1
20180243463 Chatterjee et al. Aug 2018 A1
20180243464 Hwang et al. Aug 2018 A1
20180244857 Lee et al. Aug 2018 A1
20180272052 Locke et al. Sep 2018 A1
20180296397 Askem et al. Oct 2018 A1
20180303873 Been et al. Oct 2018 A1
20180311419 Locke et al. Nov 2018 A1
20180333522 Pratt et al. Nov 2018 A1
20180344533 Rovaniemi Dec 2018 A1
20180353334 Locke et al. Dec 2018 A1
20180353337 Locke Dec 2018 A1
20180353339 Locke et al. Dec 2018 A1
20180353340 Robinson et al. Dec 2018 A1
20180353344 Locke et al. Dec 2018 A1
20180353662 Locke et al. Dec 2018 A1
20180353663 Locke et al. Dec 2018 A1
20180360667 Droche Dec 2018 A1
20190000677 Munro Jan 2019 A1
20190015258 Gowans et al. Jan 2019 A1
20190015468 Yadav et al. Jan 2019 A1
20190030223 Lin Jan 2019 A1
20190046682 Choi et al. Feb 2019 A1
20190060127 Locke et al. Feb 2019 A1
20190083752 Howell et al. Mar 2019 A1
20190117465 Osborne et al. Apr 2019 A1
20190117466 Kazala, Jr. et al. Apr 2019 A1
20190117861 Locke et al. Apr 2019 A1
20190125590 Rehbein et al. May 2019 A1
20190133830 Bishop et al. May 2019 A1
20190151155 Bonn May 2019 A1
20190151159 Gowans et al. May 2019 A1
20190151495 Helary et al. May 2019 A1
20190184052 Ilan et al. Jun 2019 A1
20190231600 Locke et al. Aug 2019 A1
20190231602 Locke et al. Aug 2019 A1
20190231943 Robinson et al. Aug 2019 A1
20190274889 Steward et al. Sep 2019 A1
20190282728 Kellar et al. Sep 2019 A1
20190290799 Arshi et al. Sep 2019 A1
20190298249 Bates et al. Oct 2019 A1
20190298577 Locke et al. Oct 2019 A1
20190298578 Shulman et al. Oct 2019 A1
20190298579 Moore et al. Oct 2019 A1
20190298580 Hall et al. Oct 2019 A1
20190298582 Addison et al. Oct 2019 A1
20190298881 Ramjit et al. Oct 2019 A1
20190298882 Nelson Oct 2019 A1
20190298895 Selby et al. Oct 2019 A1
20190307611 Askem et al. Oct 2019 A1
20190307612 Hartwell et al. Oct 2019 A1
20190307934 Allen et al. Oct 2019 A1
20190307935 Simmons et al. Oct 2019 A1
20190314187 Emslander et al. Oct 2019 A1
20190314209 Ha et al. Oct 2019 A1
20190314544 Filho et al. Oct 2019 A1
20190321232 Jardret et al. Oct 2019 A1
20190321509 Chakravarthy et al. Oct 2019 A1
20190321526 Robinson et al. Oct 2019 A1
20190322795 Kubo et al. Oct 2019 A1
20190328580 Emslander et al. Oct 2019 A1
20190336343 Etchells et al. Nov 2019 A1
20190336344 Locke Nov 2019 A1
20190336345 Bannwart Nov 2019 A1
20190336346 Locke et al. Nov 2019 A1
20190336640 Vismara et al. Nov 2019 A1
20190336641 Nisbet Nov 2019 A1
20190336643 Luukko et al. Nov 2019 A1
20190336658 Heaton et al. Nov 2019 A1
20190336739 Locke et al. Nov 2019 A1
20190343687 Locke et al. Nov 2019 A1
20190343889 Luukko et al. Nov 2019 A1
20190343979 Kearney et al. Nov 2019 A1
20190343993 Weston Nov 2019 A1
20190343994 Greener Nov 2019 A1
20190344242 Kim et al. Nov 2019 A1
20190350763 Pratt et al. Nov 2019 A1
20190350764 Zochowski et al. Nov 2019 A1
20190350765 Heagle et al. Nov 2019 A1
20190350775 Biasutti et al. Nov 2019 A1
20190350970 Saphier et al. Nov 2019 A1
20190351092 Silver et al. Nov 2019 A1
20190351093 Stein et al. Nov 2019 A1
20190351094 Maher et al. Nov 2019 A1
20190351095 Maher et al. Nov 2019 A1
20190351111 Locke et al. Nov 2019 A1
20190358088 Lavocah et al. Nov 2019 A1
20190358361 Mcinnes et al. Nov 2019 A1
20190358372 Askem et al. Nov 2019 A1
20190365948 Deegan et al. Dec 2019 A1
20190365962 Lee et al. Dec 2019 A1
20190374408 Robles et al. Dec 2019 A1
20190374673 Hoefinghoff et al. Dec 2019 A1
20190380878 Edwards et al. Dec 2019 A1
20190380881 Albert et al. Dec 2019 A1
20190380882 Taylor et al. Dec 2019 A1
20190380883 Macphee et al. Dec 2019 A1
20190381222 Locke et al. Dec 2019 A9
20190388577 Chandrashekhar-Bhat et al. Dec 2019 A1
20190388579 Macphee et al. Dec 2019 A1
20190388589 Macphee et al. Dec 2019 A1
20200000640 Mondal et al. Jan 2020 A1
20200000642 Waite Jan 2020 A1
20200000643 Locke Jan 2020 A1
20200000955 Andrews et al. Jan 2020 A1
20200000956 Huang et al. Jan 2020 A1
20200000960 Kellar et al. Jan 2020 A1
20200000985 Seddon et al. Jan 2020 A1
20200008981 Wheldrake Jan 2020 A1
20200009289 Torabinejad et al. Jan 2020 A1
20200009400 Ribeiro et al. Jan 2020 A1
20200017650 Young et al. Jan 2020 A1
20200022844 Blott et al. Jan 2020 A1
20200023102 Powell Jan 2020 A1
20200023103 Joshi et al. Jan 2020 A1
20200023104 Eriksson et al. Jan 2020 A1
20200023105 Long et al. Jan 2020 A1
20200023106 Carroll et al. Jan 2020 A1
20200030153 Johannison et al. Jan 2020 A1
20200030480 Choi Jan 2020 A1
20200030499 Menon et al. Jan 2020 A1
20200038023 Dunn Feb 2020 A1
20200038249 Pratt et al. Feb 2020 A1
20200038250 Edwards et al. Feb 2020 A1
20200038251 Locke et al. Feb 2020 A1
20200038252 Spiro Feb 2020 A1
20200038283 Hall et al. Feb 2020 A1
20200038470 Datt et al. Feb 2020 A1
20200038544 Grover et al. Feb 2020 A1
20200038546 Dizio et al. Feb 2020 A1
20200038639 Patel et al. Feb 2020 A1
20200046565 Barta et al. Feb 2020 A1
20200046566 Carey et al. Feb 2020 A1
20200046567 Carroll et al. Feb 2020 A1
20200046568 Sexton Feb 2020 A1
20200046663 Murdock et al. Feb 2020 A1
20200046876 Liu Feb 2020 A1
20200046887 Runquist et al. Feb 2020 A1
20200054491 Hentrich et al. Feb 2020 A1
20200054781 Weiser et al. Feb 2020 A1
20200060879 Edwards et al. Feb 2020 A1
20200061253 Long et al. Feb 2020 A1
20200061254 Joshi et al. Feb 2020 A1
20200061379 Bogie et al. Feb 2020 A1
20200069183 Rice et al. Mar 2020 A1
20200069476 Randolph et al. Mar 2020 A1
20200069477 Holm et al. Mar 2020 A1
20200069478 Jabbarzadeh et al. Mar 2020 A1
20200069479 Buan et al. Mar 2020 A1
20200069835 Hissink et al. Mar 2020 A1
20200069850 Beadle et al. Mar 2020 A1
20200069851 Blott et al. Mar 2020 A1
20200069853 Hall et al. Mar 2020 A1
20200078223 Locke et al. Mar 2020 A1
20200078224 Carroll et al. Mar 2020 A1
20200078225 Grillitsch et al. Mar 2020 A1
20200078305 Auvinen et al. Mar 2020 A1
20200078330 Gay Mar 2020 A1
20200078482 Yoon et al. Mar 2020 A1
20200078499 Gadde et al. Mar 2020 A1
20200085625 Bellini et al. Mar 2020 A1
20200085626 Braga et al. Mar 2020 A1
20200085629 Locke et al. Mar 2020 A1
20200085630 Robinson et al. Mar 2020 A1
20200085632 Locke et al. Mar 2020 A1
20200085991 Coomber Mar 2020 A1
20200085992 Locke et al. Mar 2020 A1
20200086014 Locke et al. Mar 2020 A1
20200086017 Jardret et al. Mar 2020 A1
20200086049 Park et al. Mar 2020 A1
20200093646 Locke et al. Mar 2020 A1
20200093756 Sabacinski Mar 2020 A1
20200093953 Kim et al. Mar 2020 A1
20200093954 Leise, III Mar 2020 A1
20200093970 Hunt et al. Mar 2020 A1
20200095421 Kettel Mar 2020 A1
20200100945 Albert et al. Apr 2020 A1
20200101192 Folwarzny Apr 2020 A1
20200107964 Locke et al. Apr 2020 A1
20200107965 Greener Apr 2020 A1
20200107966 Francis Apr 2020 A1
20200107967 Holm et al. Apr 2020 A1
20200108169 Hu et al. Apr 2020 A1
20200113741 Rehbein et al. Apr 2020 A1
20200114039 Wang et al. Apr 2020 A1
20200114040 Waite et al. Apr 2020 A1
20200114049 Wall Apr 2020 A1
20200121509 Locke et al. Apr 2020 A1
20200121510 Hartwell et al. Apr 2020 A1
20200121513 Townsend et al. Apr 2020 A1
20200121521 Daniel et al. Apr 2020 A1
20200121833 Askem et al. Apr 2020 A9
20200129338 Gardiner et al. Apr 2020 A1
20200129341 Coulthard et al. Apr 2020 A1
20200129648 Drury et al. Apr 2020 A1
20200129654 Bouvier et al. Apr 2020 A1
20200129655 Gardiner et al. Apr 2020 A1
20200129675 Robinson et al. Apr 2020 A1
20200138754 Johnson May 2020 A1
20200139002 Dudnyk et al. May 2020 A1
20200139023 Haggstrom et al. May 2020 A1
20200139025 Robinson et al. May 2020 A1
20200141031 Kosan et al. May 2020 A1
20200146894 Long et al. May 2020 A1
20200146896 Rice et al. May 2020 A1
20200146897 Locke et al. May 2020 A1
20200146899 Pratt et al. May 2020 A1
20200155355 Hill et al. May 2020 A1
20200155358 Wheldrake May 2020 A1
20200155359 Carroll et al. May 2020 A1
20200155361 Pigg et al. May 2020 A1
20200155379 Shaw et al. May 2020 A1
20200163802 Hunt et al. May 2020 A1
20200163803 Pigg et al. May 2020 A1
20200164112 Kato et al. May 2020 A1
20200164120 Jaecklein et al. May 2020 A1
20200170841 Waite et al. Jun 2020 A1
20200170842 Locke Jun 2020 A1
20200170843 Collinson et al. Jun 2020 A1
20200171197 Hubbell et al. Jun 2020 A1
20200179300 Urban et al. Jun 2020 A1
20200179558 Munro et al. Jun 2020 A1
20200179673 Wan Jun 2020 A1
20200188179 Bugedo-Albizuri et al. Jun 2020 A1
20200188180 Akbari et al. Jun 2020 A1
20200188182 Sanders et al. Jun 2020 A1
20200188183 Hamerslagh et al. Jun 2020 A1
20200188550 Dagger et al. Jun 2020 A1
20200188564 Dunn Jun 2020 A1
20200190310 Meyer Jun 2020 A1
20200197227 Locke et al. Jun 2020 A1
20200197228 Hartwell Jun 2020 A1
20200197559 Bourdillon et al. Jun 2020 A1
20200197580 Kilpadi et al. Jun 2020 A1
20200206035 Kantor et al. Jul 2020 A1
20200206036 Robinson et al. Jul 2020 A1
20200214637 Brownhill et al. Jul 2020 A1
20200214897 Long et al. Jul 2020 A1
20200214898 Waite et al. Jul 2020 A1
20200214899 Locke et al. Jul 2020 A1
20200215220 Schomburg et al. Jul 2020 A1
20200215226 Kitagawa et al. Jul 2020 A1
20200222469 Cotton Jul 2020 A1
20200229983 Robinson et al. Jul 2020 A1
20200230283 Yang et al. Jul 2020 A1
20200237562 Rice et al. Jul 2020 A1
20200237564 Hammond et al. Jul 2020 A1
20200237816 Lait Jul 2020 A1
20200246190 Luckemeyer et al. Aug 2020 A1
20200246191 Lu et al. Aug 2020 A1
20200246194 Gonzalez et al. Aug 2020 A1
20200246195 Robinson et al. Aug 2020 A1
20200253785 Bernet et al. Aug 2020 A1
20200253786 Harrison et al. Aug 2020 A1
20200253788 Rehbein et al. Aug 2020 A1
20200254139 Phillips et al. Aug 2020 A1
20200261275 Manwaring et al. Aug 2020 A1
20200261276 Lujan Hernandez et al. Aug 2020 A1
20200268560 Harrison et al. Aug 2020 A1
20200268561 Locke et al. Aug 2020 A1
20200269028 Hegg Aug 2020 A1
20200270484 Lipscomb et al. Aug 2020 A1
20200276055 Randolph et al. Sep 2020 A1
20200276058 Locke et al. Sep 2020 A1
20200277450 Silverstein et al. Sep 2020 A1
20200281519 Gowans et al. Sep 2020 A1
20200281529 Grubb et al. Sep 2020 A1
20200281678 Long et al. Sep 2020 A1
20200281775 Kushnir et al. Sep 2020 A1
20200282100 Gil et al. Sep 2020 A1
20200282114 Long et al. Sep 2020 A1
20200282115 Gardner et al. Sep 2020 A1
20200289326 Nielsen et al. Sep 2020 A1
20200289327 Hansen et al. Sep 2020 A1
20200289328 Luckemeyer et al. Sep 2020 A1
20200289346 Hansen et al. Sep 2020 A1
20200289347 Gowans et al. Sep 2020 A1
20200289701 Hall et al. Sep 2020 A1
20200289712 Jiang et al. Sep 2020 A1
20200289723 Gregory et al. Sep 2020 A1
20200289726 Locke et al. Sep 2020 A1
20200289727 Locke Sep 2020 A1
20200289806 Locke et al. Sep 2020 A1
20200297541 Hartwell et al. Sep 2020 A1
20200297543 Rodzewicz et al. Sep 2020 A1
20200297544 Moine et al. Sep 2020 A1
20200297892 Silcock Sep 2020 A1
20200297893 Ericson Sep 2020 A1
20200297894 Koyama et al. Sep 2020 A1
20200299865 Bonnefin et al. Sep 2020 A1
20200306089 Delury et al. Oct 2020 A1
20200306091 Lee et al. Oct 2020 A1
20200306092 Rehbein et al. Oct 2020 A1
20200306094 Kushnir et al. Oct 2020 A1
20200306426 Rice et al. Oct 2020 A1
20200306428 Ingram et al. Oct 2020 A1
20200306430 Rehbein et al. Oct 2020 A1
20200315853 Waite Oct 2020 A1
20200315854 Simmons et al. Oct 2020 A1
20200315894 Churilla et al. Oct 2020 A1
20200316271 Lin Oct 2020 A1
20200316272 Simpson Oct 2020 A1
20200316273 Hegg Oct 2020 A1
20200323692 Locke et al. Oct 2020 A1
20200324015 Kettel et al. Oct 2020 A1
20200330283 Locke et al. Oct 2020 A1
20200330284 Locke et al. Oct 2020 A1
20200330285 Rehbein et al. Oct 2020 A1
20200330658 Fujisaki Oct 2020 A1
20200330660 Patel et al. Oct 2020 A1
20200337719 Ingram et al. Oct 2020 A1
20200337904 Waite Oct 2020 A1
20200337905 Earl et al. Oct 2020 A1
20200337906 Long et al. Oct 2020 A1
20200337908 Long et al. Oct 2020 A1
20200338228 Kharkar et al. Oct 2020 A1
20200338243 Harrison et al. Oct 2020 A1
Foreign Referenced Citations (213)
Number Date Country
2013366038 Jul 2015 AU
101076251 Nov 2007 CN
101331263 Dec 2008 CN
105407930 Mar 2016 CN
4001690 Aug 1990 DE
0616650 Sep 1994 EP
0680344 Nov 1995 EP
1129730 Sep 2001 EP
1158859 Dec 2001 EP
1318842 Jun 2003 EP
1343510 Sep 2003 EP
1425050 Jun 2004 EP
1557088 Jul 2005 EP
1882482 Jan 2008 EP
1925719 May 2008 EP
1925917 May 2008 EP
1343510 May 2010 EP
2262545 Dec 2010 EP
2935688 Oct 2015 EP
2996730 Mar 2016 EP
3187204 Jul 2017 EP
3241439 Nov 2017 EP
3556407 Oct 2019 EP
3569260 Nov 2019 EP
3643328 Apr 2020 EP
3643330 Apr 2020 EP
3643331 Apr 2020 EP
3669838 Jun 2020 EP
3669843 Jun 2020 EP
3669844 Jun 2020 EP
2604900 Apr 1988 FR
735462 Aug 1955 GB
1105829 Mar 1968 GB
2094802 Feb 1985 GB
2220881 Jul 1992 GB
2579211 Jun 2020 GB
2579368 Jun 2020 GB
S5138427 Mar 1976 JP
H07502081 Mar 1995 JP
H08505790 Jun 1996 JP
2000201976 Jul 2000 JP
2000510539 Aug 2000 JP
2002539140 Nov 2002 JP
2003052725 Feb 2003 JP
2003510475 Mar 2003 JP
2003512095 Apr 2003 JP
2003531828 Oct 2003 JP
2007509034 Apr 2007 JP
2007167266 Jul 2007 JP
2007532606 Nov 2007 JP
2008502735 Jan 2008 JP
2008038293 Feb 2008 JP
2008503557 Feb 2008 JP
2008507327 Mar 2008 JP
2008526997 Jul 2008 JP
2009519312 May 2009 JP
2016040294 Mar 2016 JP
2016519966 Jul 2016 JP
2092180 Oct 1997 RU
9218098 Oct 1992 WO
9312275 Jun 1993 WO
9319152 Sep 1993 WO
9402022 Feb 1994 WO
8401721 May 1994 WO
9416746 Aug 1994 WO
9601119 Jan 1996 WO
9702313 Jan 1997 WO
9606260 Feb 1998 WO
9846818 Oct 1998 WO
0054593 Sep 2000 WO
0072874 Dec 2000 WO
0123653 Apr 2001 WO
0124839 Apr 2001 WO
0128338 Apr 2001 WO
0128600 Apr 2001 WO
0137936 May 2001 WO
0159421 Aug 2001 WO
0162289 Aug 2001 WO
0243743 Jun 2002 WO
02055060 Jul 2002 WO
02078755 Oct 2002 WO
03022317 Mar 2003 WO
03047341 Jun 2003 WO
03068247 Aug 2003 WO
2004028461 Apr 2004 WO
2004035718 Apr 2004 WO
2004056346 Jul 2004 WO
2004108093 Dec 2004 WO
2005018543 Mar 2005 WO
2005020915 Mar 2005 WO
2005032459 Apr 2005 WO
2005079582 Sep 2005 WO
2005099757 Oct 2005 WO
2005123103 Dec 2005 WO
2006000765 Jan 2006 WO
2006015317 Feb 2006 WO
2006022970 Mar 2006 WO
2006029213 Mar 2006 WO
2006111624 Oct 2006 WO
2007005720 Jan 2007 WO
2007068938 Jun 2007 WO
2008035734 Mar 2008 WO
2009130608 Oct 2009 WO
2010070292 Jun 2010 WO
2011121394 Oct 2011 WO
2011135284 Nov 2011 WO
2011144888 Nov 2011 WO
2012061225 May 2012 WO
2012072980 Jun 2012 WO
2012136968 Oct 2012 WO
2013015827 Jan 2013 WO
2013126049 Aug 2013 WO
2014014842 Jan 2014 WO
2014096843 Jun 2014 WO
2014186590 Nov 2014 WO
2015145117 Oct 2015 WO
2015173546 Nov 2015 WO
2016141450 Sep 2016 WO
2017016974 Feb 2017 WO
2017125250 Jul 2017 WO
2018029231 Feb 2018 WO
2018094061 May 2018 WO
2018162613 Sep 2018 WO
2018163093 Sep 2018 WO
2018189265 Oct 2018 WO
2018226667 Dec 2018 WO
2018227144 Dec 2018 WO
2018231825 Dec 2018 WO
2018236648 Dec 2018 WO
2019002085 Jan 2019 WO
2019012068 Jan 2019 WO
2019012069 Jan 2019 WO
2019022493 Jan 2019 WO
2019027933 Feb 2019 WO
2019038548 Feb 2019 WO
2019038549 Feb 2019 WO
2019040656 Feb 2019 WO
2019050855 Mar 2019 WO
2019058373 Mar 2019 WO
2019073326 Apr 2019 WO
2019083563 May 2019 WO
2019083868 May 2019 WO
2019086911 May 2019 WO
2019091150 May 2019 WO
2019094147 May 2019 WO
2019096828 May 2019 WO
2019113275 Jun 2019 WO
2019113623 Jun 2019 WO
2019191590 Oct 2019 WO
2019193141 Oct 2019 WO
2019193333 Oct 2019 WO
2019199389 Oct 2019 WO
2019199596 Oct 2019 WO
2019199687 Oct 2019 WO
2019199798 Oct 2019 WO
2019199849 Oct 2019 WO
2019200035 Oct 2019 WO
2019215572 Nov 2019 WO
2019219613 Nov 2019 WO
2019234365 Dec 2019 WO
2020005062 Jan 2020 WO
2020005344 Jan 2020 WO
2020005536 Jan 2020 WO
2020005546 Jan 2020 WO
2020005577 Jan 2020 WO
2020007429 Jan 2020 WO
2020011691 Jan 2020 WO
2020014178 Jan 2020 WO
2020014310 Jan 2020 WO
2020018300 Jan 2020 WO
2020026061 Feb 2020 WO
2020026144 Feb 2020 WO
2020033351 Feb 2020 WO
2020035811 Feb 2020 WO
2020043665 Mar 2020 WO
2020044237 Mar 2020 WO
2020046443 Mar 2020 WO
2020047255 Mar 2020 WO
2020049038 Mar 2020 WO
2020055945 Mar 2020 WO
2020056014 Mar 2020 WO
2020056182 Mar 2020 WO
2020065531 Apr 2020 WO
2020070231 Apr 2020 WO
2020074512 Apr 2020 WO
2020078993 Apr 2020 WO
2020079009 Apr 2020 WO
2020079330 Apr 2020 WO
2020081259 Apr 2020 WO
2020081391 Apr 2020 WO
2020092598 May 2020 WO
2020136555 Jul 2020 WO
2020141059 Jul 2020 WO
2020144347 Jul 2020 WO
2020150548 Jul 2020 WO
2020159675 Aug 2020 WO
2020159677 Aug 2020 WO
2020159678 Aug 2020 WO
2020159823 Aug 2020 WO
2020159859 Aug 2020 WO
2020159892 Aug 2020 WO
2020161086 Aug 2020 WO
2020173665 Sep 2020 WO
2020173760 Sep 2020 WO
2020174264 Sep 2020 WO
2020174510 Sep 2020 WO
2020182887 Sep 2020 WO
2020185810 Sep 2020 WO
2020197759 Oct 2020 WO
2020197760 Oct 2020 WO
2020198484 Oct 2020 WO
2020201879 Oct 2020 WO
2020213998 Oct 2020 WO
Non-Patent Literature Citations (265)
Entry
Hurlow J, Blanz E, Gaddy J. Clinical investigation of biofilm in non-healing wounds by high resolution microscopy techniques. J Wound Care. 2016; 25(suppl 9): S11-S22.
India Patent Application No. 9392/DELNP/2013 First Examination Report dated Feb. 23, 2018.
International Wound Infection Institute (IWII). Wound infection in clinical practice. Wounds International, 2016. http://www.woundinfection-institute.com/wp-content/uploads/2017/03/IWII-Wound-infection-in-clinical-practice.pdf. Accessed Jul. 2, 2018.
James G, Swogger E, Wolcott R et al. Biofilms in chronic wounds. Wound Repair Regen. 2008; 16: 37-44.
Japanese Patent Application No. 2017-112806 Official Action dated Mar. 6, 2018.
Japanese Patent Application No. 2013-541415 Final Rejection dated Jun. 14, 2016.
Japanese Patent Application No. 2014-242257 Office Action dated Apr. 5, 2016.
Japanese Patent Application No. 2014-242257 Office Action dated May 23, 2017.
Japanese Patent Application No. 2014-543972 Office Action dated Dec. 20, 2016.
Japanese Patent Application No. 2015-200279 Office Action dated Aug. 31, 2017.
Japanese Patent Application No. 2015-200279 Office Action dated Feb. 7, 2017.
Japanese Patent Application No. 2015-200279 Office Action dated Jul. 12, 2016.
Japanese Patent Application No. 2015-548762 Office Action dated Jul. 31, 2018.
Japanese Patent Application No. 2016-154639 Office Action dated Jun. 8, 2017.
Japanese Patent Application No. 2016-202835 Office Action dated Jun. 20, 2017.
Japanese Patent Application No. 2016-202835 Office Action dated Mar. 6, 2018.
Jasovský D, Littmann J, Zorzet A, Cars O. Antimicrobial resistance—a threat to the world's sustainable development. Upsala J Med Sci. 2016; 121: 159-64.
Johani K, Malone M, Jensen S et al. Microscopy visualisation confirms multi-species biofilms are ubiquitous in diabetic foot ulcers. Int Wound J. 2017; 14: 1160-9.
Jones et al., Antimicrobial activity of silver-containing dressings is influenced by dressing conformability with a wound surface. Wounds, 17:263-270 (2005).
JP-A-H7-504699 (English counterpart WO93/19152).
JP-A-H7-509236 (English counterpart WO94/02022).
Kapoor et al., Fluorescence and absorption spectra of Rose-Bengal dye in the presence of surfactants. Journal of Luminescence, 22(4): 429-439, 1981. (Abstract only).
Kaur et al., Effect of certain chelating agents on the antibacterial action of silver nitrate. Journal of Hygiene, Epidemiology, Microbiology and Immunology. 32(3): 299-306, 1988.
Keast D, Swanson T, Carville K, Fletcher J, Schultz G, Black J. Ten top tips . . . understanding and managing wound biofilm. Wounds International. 2014; 5: 20-3.
Kharkevich, D.A., Pharmacology: Textbook. Geotar-Media, p. 66-71, 2006.
Kim D, Namen W, Moore J, Buchanan M, Hayes V, Myntti M, Hakaim A. Clinical assessment of a biofilm-disrupting agent for the management of chronic wounds compared with standard of care: a therapeutic approach. Wounds. 2018 30: 120-30.
Kita et al., pH-Dependent preferential antibacterial activity of Ethylenediaminetetraacetic acid (EDTA). Japanese Journal of Bacteriology, 47(4):6 pages, 1992.
Kite et al., Use of in vivo-generated biofilms from hemodialysis catheters to test the efficacy of a novel antimicrobial catheter lock for biofilm eradication in vitro. J Clin Microbiol., 42.7 (2004): 3073-3076.
Kryukov et al., The role of bacteriological examination in diagnosis of chronic tonsillitis. Becthnk 3:35-38, 2008.
Lazarus G, Cooper D, Knighton D, Percoraro R, Rodeheaver G, Robson M. Definitions and guidelines for assessment of wounds and evaluation of healing. Wound Repair Regen. 1994; 2: 165-70.
Lewis K. Persister cells. Ann Rev Microbiol. 2010; 64: 357-72.
Lineaweaver et al., Topical antimicrobial toxicity. Arch Surg., 120(3):267-70 (1985).
Lipsky B, Aragón-Sánchez J, Diggle M et al. IWGDF guidance on the diagnosis and management of foot infections in persons with diabetes. Diabetes Metab Res Rev. 2016; 32: 45-74.
Lipsky B, Dryden M, Gottrup F et al. Antimicrobial stewardship in wound care: A position paper from the British society for antimicrobial chemotherapy and European wound management association. J. Antimicrob Chemother 2016; 71: 3026-35.
Lipsky B Medical treatment of diabetic foot infections. Clin Infect Dis. 2004; 39: S104-S114.
Lipsky B, Peters E, Senneville E et al. Expert opinion on the management of infections in the diabetic foot. Diabetes Metab Res Rev. 2012; 28(suppl 1): 163-78.
Macia M, Roho-Molinero E, Oliver A. Antimicrobial susceptibility testing in biofilm-growing bacteria. Clin Microbiol Infect. 2014; 20: 981-90.
Malone M, Bjarnsholt T, McBain A et al. The prevalence of biofilms in chronic wounds: a systematic review and meta-analysis of published data. J Wound Care. 2017; 26: 20-5.
McDonnell G, Russell A. Antiseptics and disinfectants: Activity, action, and resistance. Clin Microbiol Rev. 1999; 12: 147-79.
Meredith K, Burke N, Brownley H et al. Antimicrobial efficacy of enhanced and standard silver wound dressings in an in vitro mature bioburden model. Symposium on Advanced Wound Care. 2018 Poster presentation: Las Vegas.
Metcalf D, Bowler P. Biofilm delays wound healing: A review of the evidence. Burns Trauma. 2013; 1; 5-12.
Metcalf D, Bowler P. Clinical Impact of an enhanced antimicrobial dressing in non-healing wounds previously managed with antibiotics. Symposium on Advanced Wound Care. 2018 Poster presentation: Las Vegas.
Metcalf D, Bowler P, Parsons D. In: Dhanasekaran D, ed. Wound Biofilm and Therapeutic Strategies, Microbial Biofilms—Importance and Applications. Rijeka, Croatia: InTech; 2016. https://www.intechopen.com/books/microbial-importance-and-applications/wound-biofilm-and-therapeutic-strategies. Accessed Aug. 8, 2018.
Metcalf D, Parsons D, Bowler P. A next-generation antimicrobial wound dressing: a real-life clinical evaluation in the UK and Ireland. J Wound Care. 2016; 25: 132-8.
Mexican Patent Application No. MX/a/2013/006090 Official Action dated Jun. 7, 2016.
Muller et al. pH-dependent formation of ethylenediaminetetraacetic acid supramolecular aggregates. FEBS Lett 340: 17-21 (1994).
Nagai et al., Suppressive effects of EDTA for Pseudomonas aeruginosa products biofilm STN CAPLUS, Jan. 1, 1996, 1 page. XP002122029.
Nagoba B, Suryawanshi N, Wadher B, Selkar S. Acidic environment and wound healing: a review. Wounds. 2015; 27: 5-11.
Newman G, Walker M, Hobot J, Bowler P. Visualisation of bacterial sequestration and bactericidal activity within hydrating Hydrofiber wound dressings. Biomaterials. 2006; 27: 1129-39.
Nickel J, Wright J, Ruseska I, Marrie T, Whitfield C, Costerton J. Antibiotic resistance of pseudomonas aeruginosa colonizing a urinary catheter in vitro. Eur J Clin Microbiol. 1985; 4: 213-18.
Nix D, Pierce B, Haugen V. Eliminating non-compliance. In Bryant R and Nix D, eds. Acute and Chronic Wounds Current Management Concepts. 5th ed. St. Louis, MO: Elsevier; 2016: 428-40.
Nussbaum S, Carter M, Fife C et al. An economic evaluation of the impact, cost, and Medicare policy implications of chronic nonhealing wounds. Value Health. 2018; 21: 27-32.
Olsen I. Biofilm- specific antibiotic tolerance and resistance. Eur J Clin Microbiol Infect Dis. 2015; 34: 877-86.
Ono N. A Semi-quantitative measurement of glycocalyx and an ATP bioluminescent assay for the analysis of Pseudomonas Aeruginosa biofilm. The Japanese Journal of Urology, 86(9):1440-1449, 1995.
Ovington, The Value of Silver in Wound Management. Podiatry Today, Dec. 1999, 12(7):59-62. (marked as Exhibit 3 at the Deposition of Fiona Adam).
Parikh et al., Antimicrobial silver/sodium carboxymethyl cotton dressings for burn wounds Textile Research Journal, 75 (2):134-138 (2005).
Parsons et al., Enhanced Performance and Mode of Action of a Novel Antibiofilm Hydrofiber Wound Dressing. BioMed Research International 2016: ID 7616471:1-14 (2016).
PCT Patent Application No. PCT/GB2012/000329 International Search Report and Written Opinion dated Jul. 17, 2012.
PCT Patent Application No. PCT/US2014/038224 International Preliminary Report on Patentability dated Nov. 17, 2015.
PCT Patent Application No. PCT/US2014/038224 International Search Report dated Sep. 15, 2014.
PCT Patent Application No. PCT/US2014/038224 Written Opinion dated Sep. 15, 2014.
PCT Patent Application No. PCT/GB2006/004691 International Preliminary Report on Patentability dated Aug. 12, 2008.
PCT Patent Application No. PCT/GB2006/004691 International Search Report dated Jul. 7, 2008.
PCT Patent Application No. PCT/GB2006/004691 Written Opinion dated Jul. 7, 2008.
PCT Patent Application No. PCT/GB2009/002912 International Preliminary Report on Patentability dated Jun. 21, 2011.
PCT Patent Application No. PCT/GB2009/002912 International Search Report and Written Opinion dated Mar. 2, 2010.
PCT Patent Application No. PCT/GB2011/001665 International Preliminary Report on Patentability dated Jun. 4, 2013.
PCT Patent Application No. PCT/GB2011/001665 International Search Report dated Mar. 2, 2012.
PCT Patent Application No. PCT/GB2011/001665 Written Opinion dated Mar. 2, 2012.
Pennington JA., A review of iodine toxicity reports. J Am Diet Assoc., 90(11):1571-81 (1990).
Percival et al., Tetrasodium EDTA as a novel central venous catheter lock solution against biofilm DATA Biosis (online), Jun. 1, 2005, 6 pages XP002485725.
Percival S, Bowler P. Biofilms and their potential role in wound healing. Wounds. 2004; 16: 234-240.
Petchiappan A, Chatterji D. Antibiotic resistance: Current perspectives. ACS Omega 2017, 2, 7400-7409. https://www.researchgate.net/publication/321019969/download. Accessed Jul. 7, 2018.
Phillips T. Chronic cutaneous ulcers: Etiology and epidemiology. J Invest Dermatol. 1994; 102: 38S-41S.
Poon and Burd, In vitro cytotoxity of silver: implication for clinical wound care. Burns. 30(2):140-7 (2004).
Ramage et al., Inhibition on Candida albicans bioflim formation using divalent cation chelators (EDTA) Mycopathologia, Kluwer Academic Publishers, 164(6):301-306 (2007). XP019555313.
Reybrouck et al., Effect of ethylenediamine tetraacetate on the germicidal action of disinfectants against “Pseudomona.” Acta Clinica Belgica, 24(1):32-41, 1969.
Rhoads D, Wolcott R, Percival S. Biofilms in wounds: management strategies. J Wound Care. 2008; 17: 502-9.
Rodeheaver G, Ratliff C. Wound cleansing, wound irrigation, wound disinfection. In: Krasner D, van Rijswijk L, eds. Chronic Wound Care: The Essentials e-Book. Malvern, PA: HMP; 2018: 47-62. Available at: https://s3.amazonaws.com/whywoundcare/Files/Chapter+5.pdf. Accessed Jul. 7, 2018.
Romanelli M, Vowden K, Weir D. Exudate management made easy. Wounds International. 2014. http://www.woundsinternational.com/made-easys/view/exudate-management-made-easy-1. Accessed Jul. 11, 2018.
Rondas A, Schols J, Stobberingh E, Price P. Definition of infection in chronic wounds by Dutch nursing home physicians. Int Wound J. 2006; 6: 267-74.
Russian Patent Application No. 2015153446 Office Action and Search Report dated Apr. 23, 2018.
Russian Patent Application No. 2013129866 Office Action dated Oct. 21, 2016.
Russian Patent Application No. 2013129866/10 Protocol of a Meeting with the Examiner dated Jun. 14, 2017.
Russian Patent Application No. 2013149176 Official Action dated Feb. 21, 2018.
Russian Patent Application No. 2013149176 Official Action dated Jun. 2, 2016.
Russian Patent Application No. 2015153446 Office Action dated Feb. 10, 2016 (In Russian).
Said et al., An in vitro test of the efficacy of an anti-biofilm wound dressing. Int J Pharm. 474(1-2):177-181 (2014).
Saudi Arabia Patent Application No. 515370133 2nd Examination Report dated Feb. 6, 2017.
Saudi Arabia Patent Application No. 515370133 Examination Report dated Oct. 18, 2016.
Savage V, Chopra I, ONeill A. Staphylococcus aureus biofilms promote horizontal transfer of antibiotic resistance. Antimicrob Agents Chemother. 2013; 57: 1968-70.
Sen C, Gordillo G, Roy S et al. Human skin wounds: A major and snowballing threat to public health and the economy. Wound Repair Regen. 2009; 17: 763-71.
Senter, A Textbook of Organic Chemistry, Fifth Ed. 1919, pp. 435-443.
Seth A, Zhong A, Nguyen K et al. Impact of a novel, antimicrobial dressing on in vivo, Pseudomonas aeruginosa wound biofilm: quantitative comparative analysis using a rabbit ear model. Wound Repair Regen. 2014; 22: 712-9.
Shanmugam V, Couch K, McNish S, Amdur R. Relationship between opioid treatment and rate of healing in chronic wounds. Wound Repair Regen. 2017; 25: 120-30.
Sharma et al., Toluidine blue-mediated photodynamic effects on Staphylococcal biofilms. Antimicrobial Agents and Chemotherapy, 52(1):299-305, 2008.
Smith and Nephew, OTC mediation information: Dermal wound cleanser—benzethonium chloride spray Dec. 17, 2009, p. 1-6. XP55031919.
Song T, Duperthuy M, Nyunt-Wai, S. Sub-optimal treatment of bacterial biofilms. Antibiotics. 2016; 5: 1-18.
Spellberg B, Srinivasan A, Chambers H. New societal approaches to empowering antibiotic stewardship. JAMA. 2016; 315: 1229-30.
Stevens D, Bisno A, Chambers H et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis. 2014; 59: 147-59.
Chinese Patent Application No. 201180066375.2 Office Action dated Sep. 26, 2016.
Chinese Patent Application No. 201180066375.2 Reexamination Decision dated Dec. 20, 2017.
Chinese Patent Application No. 201280027537.6 Third Office Action dated Mar. 2, 2016.
Chinese Patent Application No. 201280027537.6 Decision of Reexamination dated Oct. 27, 2017.
Chinese Patent Application No. 201280027537.6 Office Action dated Sep. 12, 2016.
Chinese Patent Application No. 201480028155.4 Decision on Rejection dated Nov. 21, 2018.
Chinese Patent Application No. 201480028155.4 First Office Action dated Apr. 18, 2017.
Ciofu O, Rojo-Molinero E, Macia M, Oliver A. Antibiotic treatment of biofilm infections. APMIS. 2017; 125:304-19.
Costerton J, Geesey G, Cheng K. How bacteria stick. Sci Am. 1978; 238:86-95.
Costerton J, Irvin R, Cheng K. The bacterial glycocalyx in nature and disease. Ann Rev Microbiol. 1981; 35:299-324.
Costerton J, Stewart P, Greenberg E. Bacterial biofilms: a common cause of persistent infections. Science. 1999; 284: 1318-22.
Costerton JW. Bacterial biofilms in nature and disease. Ann Rev Microbiol. 1987; 41:435-64.
Database Biosis, Biosciences Information Service, Philadelphia, PA, 1992, Kida N., etaL, Effect of PH on Preferential Antibacterial Activity of Ethylenediaminetetraacetic Acid EDTA, XP002485724, Database Accession No. PREV199294118093.
Database Biosis, Biosciences Information Service, Philadelphia, PA, 2005, Percival, L, et al.. Effect of PH on Tetrasodium EDTA as a novel central venous catheter lock solution against biofilm, XP002485725, Database Accession No. PREV200600021247.
Database CA, Chemical Abstracts Service, Columbus, OH, US; Izzat, I.N., et al., Effect of varying concentrations of EDTA on the antimicrobial properties of cutting fluid preservatives, 1979, XP002485722, STN-International Database Accession No. 93:62380.
Database CA, Chemical Abstracts Service, Columbus, OH, US; Reybrouck, G., et al., Effect of ethylenediaminetetraacetate on the germicidal action of disinfectants against Pseudomonas aeruginosa, XP002485721, STN-International Database Accession No. 72:11588, 1969.
Database Medline, US National Library of Medicine, Bethesda, MD, 1988, Kaur, P., et al., Effect of certain chelating agents on the antibacterial action of silver nitrate, XP002485723, STN-International Database Accession No. NLM3143759.
Demidova and Hamblin, Photodynamic therapy targeted to pathogens Int. J. Immunopathol Pharmacol., 17 (3):245-254, 2004.
Dini V, Salvo P, Janowska A, Di Francesco F, Barbini A, Romanelli M. Correlation between wound temperature obtained with an infrared camera and clinical wound bed score in venous leg ulcers. Wounds. 2015; 27:274-8.
Dougherty et al., Photodynamic therapy. Journal of the National Cancer Institute, 90(12):889-905, 1998.
Doughty D, Sparks B. Wound healing physiology and factors that affect the wound repair process. In Bryant R and Nix D, eds. Acute and Chronic Wounds: Current Management Concepts. 5th ed. St. Louis, MO: Elsevier; 2016:63-81.
Eming S, Martin P, Tomic-Canic M. Wound repair and regeneration: mechanisms, signaling, and translation. Sci Transl Med. 2014; 6: 57-72. doi: 10.1126/scitranslmed.3009337.
Etebu E, Arikekpar I. Antibiotics: Classification and mechanisms of action with emphasis on molecular perspective. Int J of Appl Microbiol and Biothech Res. 2016; 4:90-101. http://www.bluepenjournals.org/ijambr/pdf/2016/October/Etebu_and_Arikekpar.pdf. Accessed Aug. 8, 2018.
European Centre for Disease Prevention and Control (ECDC). Proposals for EU Guidelines on the Prudent Use of Antimicrobials in Humans. Stockholm: ECDC; 2017. http://ecdc.europa.eu/en/publications/_layouts/forms/Publication_DispForm.aspx?List=4f55ad51-4aed-4d32-b690-af70113dbb90&ID-1643. Accessed Jul. 2, 2018.
European Patent Application No. 09795521.5 Communication dated Mar. 24, 2017.
European Patent Application No. 09795521.5 Office Action dated May 9, 2018.
European Patent Application No. 12719420.7 Communication dated Jul. 20, 2016.
European Patent Application No. 12719420.7 Examination Report dated Apr. 5, 2017.
European Patent Application No. 12719420.7 Examination Report dated Aug. 7, 2018.
European Patent Application No. 14797983.5 Supplementary European Search Report dated Dec. 6, 2016.
European Patent Application No. 17163418.1 extended European Search Report dated Sep. 17, 2017.
European Patent Application No. 06820530.1 Communication dated Apr. 7, 2016.
European Patent Application No. 06820530.1 Communication dated Jan. 30, 2013.
European Patent Application No. 06820530.1 Communication dated Mar. 30, 2009.
FDA website on Medical Devices, Premarket Notification (510k), 4 pages, 2013.
Fife C, Carter M, Walker D, Thomson B. Wound care outcomes and associated cost among patients treated in US outpatient wound centers: Data from the US Wound Registry. Wounds. 2012; 24: 10-7.
Finnegan S, Percival S. EDTA: an antimicrobial and antibiofilm agent for use in wound care. Adv Wound Care. 2015; 4: 415-21.
Fleming D, Rumbaugh K. Approaches to dispersing medical biofilms. Microorganisms. 2017; 5: 1-16.
Frykberg R, Banks J. Challenges in the treatment of chronic wounds. Adv Wound Care. 2015; 4: 560-82.
Gardner S, Frantz R, Doebbeling B. The validity of the clincal signs and symptoms used to identify localized chronic wound infection. Wound Repair Regen. 2001; 9: 178-86.
Gardner S, Hillis S, Frantz R. Clinical signs of infection in diabetic foot ulcers with high microbial load. Biol Res Nurs. 2009; 11: 119-28.
Gilbert, et al., The Use of Poloxamer Hydrogels for the Assessment of Biofilm Suspectibility Towards Biocide Treatments, Journal of Applied Microbiology, 1998, 85: 985-990.
Gilchrist M, Seaton R. Outpatient parenteral antimicrobial therapy and antimicrobial stewardship: challenges and checklists. J Antimicrob Chemother. 2015; 70: 965-70.
Gottrup F. A specialized wound-healing center concept: importance of a multidisciplinary department structure and surgical treatment facilities in the treatment of chronic wounds. Am J Surg. 2004; 187: S38-S43.
Gottrup F, Apelqvist J, Bjarnsholt T et al. Antimicrobials and non-healing wounds: Evidence, controversies and suggestions—key messages. J Wound Care. 2014; 23: 477-8, 480, 482.
Guest JF, Vowden K. The health economic burden that acute and chronic wounds impose on an average clinical commissioning group/health board in the UK. J Wound Care. 2017; 26: 292-303.
Harding K, Szczepkowski M, Mikosiński J et al. Safety and performance evaluation of a next-generation antimicrobial dressing in patients with chronic venous leg ulcers. Int Wound J. 2016; 13: 442-8.
Harrison-Balestra et al., A wound isolated Pseudomonas aeruginosa grows a biofilm in vitro within 10 hours and is visualized by light microscopy. Dermatol. Surgery, 29(6): 631-635, 2003.
Hobot et al., Effect of Hydrofiber wound dressings on bacterial ultrastructure. J Electron Microsc (Tokyo). 50(2): 67-75 (2008).
Howell J, Stair T, Howell A, Mundt D, Falcone A, Peters S. The effect of scrubbing and irrigation with normal saline, povidone iodine, and cefazolin on wound bacterial counts in a Guinea pig model. Am J Emerg Med. 1993; 11: 134-38.
Stewart P. Antimicrobial tolerance in biofilms. Microbiol Spectrum. 2015; 3: 1-30. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4507308/pdf/nihms697879.pdf. Accessed Jul. 24, 2018.
Stotts R. Wound Bioburden. In Baranoski, S, Ayello, E. eds. Wound Care Essentials: Practice and Principles. Philadelphia, PA: Wolters Klower; 2004: 121-48.
Swisher, R.D., Surfactant effects on humans and other mammals. The Soap and Detergent Association, Scientific and Technical Report, 4:1-8, 11, 16, 17, 19, Nov. 1966.
Tallardia. Drug synergism: Its detection and applications. The Journal of Pharmacology and Experimental Therapeutics, 298(3):865-872, 2001.
Thomas and McCubbin, An in vitro analysis of the antimicrobial properties of 10 silver-containing dressings. The Journal of Wound Care, Sep. 2003, 12(8):105-108.
Thomas-Hess, C. Checklist for factors affecting wound healing. Adv Skin Wound Care. 2011; 24: 192.
Torkington-Stokes R, Metcalf D, Bowler P. Management of diabetic foot ulcers: valuation of case studies. Br J Nurs. 2016; 25: S27-S33.
Understanding biofilms. Bacteriality. Published online May 26, 2008. http://bacteriality.com/2008/05/biofilm/. Accessed Jul. 2, 2018.
United Nations. World Population Aging. New York. 2017. http://www.un.org/en/development/desa/population/publications/pdf/ageing/WPA2017_Highlights.pdf. Accessed Jul. 24, 2018.
U.S. Appl. No. 11/610,671 Office Action dated Apr. 2, 2008.
U.S. Appl. No. 11/610,671 Office Action dated Apr. 7, 2011.
U.S. Appl. No. 11/610,671 Office Action dated Aug. 17, 2009.
U.S. Appl. No. 11/610,671 Office Action dated Dec. 3, 2008.
U.S. Appl. No. 11/610,671 Office Action dated Feb. 18, 2010.
U.S. Appl. No. 11/610,671 Office Action dated Mar. 11, 2015.
U.S. Appl. No. 11/610,671 Office Action dated Mar. 20, 2014.
U.S. Appl. No. 11/610,671 Office Action dated Oct. 20, 2011.
U.S. Appl. No. 11/610,671 Office Action dated Oct. 8, 2014.
U.S. Appl. No. 11/610,671 Office Action dated Sep. 12, 2013.
U.S. Appl. No. 12/406,316 Office Action dated Apr. 4, 2012.
U.S. Appl. No. 12/406,316 Office Action dated Apr. 5, 2013.
U.S. Appl. No. 12/406,316 Office Action dated Aug. 10, 2011.
U.S. Appl. No. 12/406,316 Office Action dated Nov. 26, 2012.
U.S. Appl. No. 14/114,517 Office Action dated Aug. 13, 2015.
U.S. Appl. No. 13/990,755 Office Action dated Jan. 19, 2017.
U.S. Appl. No. 09/997,545 Office Action dated Feb. 10, 2003.
U.S. Appl. No. 09/997,545 Office Action dated Jul. 3, 2002.
U.S. Appl. No. 10/734,784 Office Action dated Apr. 4, 2007.
U.S. Appl. No. 13/124,472 Office Action dated Feb. 16, 2016.
U.S. Appl. No. 13/124,472 Office Action dated Jan. 18, 2013.
U.S. Appl. No. 13/124,472 Office Action dated Jun. 21, 2013.
U.S. Appl. No. 13/124,472 Office Action dated Jun. 4, 2015.
U.S. Appl. No. 13/124,472 Office Action dated Oct. 3, 2014.
U.S. Appl. No. 13/990,755 Office Action dated Jun. 29, 2017.
U.S. Appl. No. 13/990,755 Office Action dated May 5, 2016.
U.S. Appl. No. 14/114,517 Office Action dated Apr. 23, 2015.
U.S. Appl. No. 14/114,517 Office Action dated Mar. 24, 2016.
U.S. Appl. No. 14/114,517 Office Action dated Oct. 20, 2016.
U.S. Appl. No. 14/795,176 Office Action dated Feb. 3, 2016.
U.S. Appl. No. 14/889,818 Office Action dated Jan. 25, 2017.
Japanese Office Action; Japan Patent Office; Japanese Patent Application No. 2018-223751; dated Sep. 15, 2020; 4 pages.
PCT/GB2013/053374 International Preliminary Report on Patentability dated Jul. 2, 2015.
PCT/GB2013/053374 International Search Report dated Jul. 24, 2014.
PCT/GB2013/053374 Written Opinion dated Jul. 24, 2014.
PCT/US01/044773 International Search Report dated Aug. 31, 2001.
PCT/US01/044773 International Preliminary Report on Patentability completed Mar. 10, 2003.
Chinese Patent Application No. 201380073403.2 First Office Action dated Aug. 16, 2016.
European Patent Application No. 13821122.2 Communication dated Oct. 25, 2016.
Australian Patent Application No. 2013366038 Examination Report No. 1 dated Jun. 20, 2017.
Chinese Patent Application No. 201380073403.2 Office Action dated Jul. 3, 2017.
Chile Patent Application No. 3274-2015 Second Office Action dated Jan. 22, 2018.
Japanese Patent Application No. 2016-514095 Office Action dated Feb. 20, 2018.
U.S. Appl. No. 14/889,818 Office Action dated Jan. 10, 2018.
Australian Patent Application No. 2013366038 Examination Report No. 2 dated Jun. 19, 2018.
Australian Patent Application No. 2014265336 Examination Report No. 2 dated Mar. 26, 2018.
Chinese Patent Application No. 201380073403.2 Third Office Action dated Mar. 26, 2018.
Chinese Patent Application No. 201480028155.4 Office Action dated Mar. 22, 2018.
Mexican Patent Application No. MX/a/2015/015197 Office Action dated Mar. 2, 2018.
Taiwanese Patent Application No. 103117207 Office Action dated Apr. 11, 2018.
U.S. Appl. No. 14/889,818 Office Action dated Jun. 19, 2018.
510(k) Premarket Notification, AQUACEL and AQUACEL Ag, Section 5: 510(k) Summary revised Apr. 21, 2008, 6 pages.
AMR: a major European and Global challenge: fact sheet. Antimicrobial Resistance—European Commission (EC-AMR) 08, Sep. 2017. https://ec.europa.eu/health/amr/sites/amr/files/amr_factsheet_en.pdf. Accessed Jul. 2, 2018.
Anmar H, Dasgupta M, Costerton J. Testing the susceptibility of bacteria in biofilms to antibacterial agents. Antimicrob Agents Chemother. 1990, 34:2043-2046.
Arata, J. Staphylococcus aureus and the skin. Japanese Journal of Chemotherapy, 49(3):147-156, 2001.
Australian Patent Application No. 2014265336 Examiner's First Report dated Mar. 29, 2017.
Australian Patent Application No. 2017201084 Examination Report No. 1 dated May 18, 2018.
Banin et al., Chelator-induced dispersal and killing of Pseudomonas aeruginosa cells in a biofilm. Applied and Environmental Microbiology, 72(3):2064-2069, 2006.
Bay L, Kragh K, Eickhardt S, et al. Bacterial aggregates establish at the edges of acute epidermal wounds. Adv Wound Care. 2018; 7:105-13.
Bohn G, Liden B, Schultz G, et al. Ovine-based collagen matrix dressing: Next-generation callagen dressing for wound care. Adv Wound Care. 2016; 5:1-10.
Bowler et al., Dressing conformability and silver-containing wound dressings. Wounds U.K., 6:14-20 (2010).
Bowler P. Antibiotic resistance and biofilm tolerance: a combined threat in the treatment of chronic infections. J Wound Care. 2018 27:273-277.
Bowler P, Jones S, Davies B, Coyle E. Infection control properties of some wound dressings. J Wound Care. 1999; 8:499-502.
Bowler P, Jones S, Towers V, et al. Dressing conformability and silver-containing wound dressings. Wounds UK. 2010; 6:14-20.
Bowler P, Parsons D. Combatting wound biofilm and recalcitrance with a novel anti-biofilm Hydrofiber® wound dressing. Wound Medicine. 2016; 14:6-11.
Bryant R, Nix D. Principles for practice development to facilitate outcomes and productivity. In Bryant R and Nix D, eds. Acute and Chronic Wounds: Current Management Concepts. 5th ed. St. Louis, MO: Elsvier; 2016:1-20.
Canadian Patent Application No. 2,834,871 Office Action dated Oct. 1, 2018.
Canadian Patent Application No. 2,745,059 Office Action dated Apr. 20, 2018.
Canadian Patent Application No. 2,745,059 Office Action dated Aug. 2, 2017.
Canadian Patent Application No. 2,745,059 Office Action dated Oct. 25, 2016.
Canadian Patent Application No. 2,819,303 Office Action dated Oct. 24, 2017.
Canadian Patent Application No. 2,834,871 Office Action dated Jan. 31, 2018.
Capinera et al., Insectional activity of photoactive dyes to American and migratory grasshoppers (Orthoptera Acrididae). J. Econ. Entomol., 92(3):662-666, 2000.
Cavaliere R, Ball J, Turnbull L, Whitchurch C. The biofilm matrix destabilizers, EDTA and DNasel, enhance the susceptibility of nontypeable Hemophilus influenzae biofilms to treatment with ampicillin and ciprofloxacin. Microbiology. 2014; 3:557-67.
Centers for Disease Control and Prevention. Antibiotic Resistance Threats in the United States. 2013. http://www.cdc.gov/drugresistance/threat-report-2013/pdf/ar-threats-2013-508.pdf. Accessed Aug. 1, 2018.
Ceri et al., The Calgary biofilm device: New technology for rapid determination of antibiotic susceptibilities of bacterial biofilms. Journal of Clinical Microbiology, 37(6):1771-1776, 1999.
Chan B, Cadarette S, Wodchis W, Wong J, Mittmann N, Kran M. Cost-of-illness studies in chronic ulcers: A systemic review. J Wound Care. 2017; 26:S4-S15.
Chemburu et al., Light-induced biocidal action of conjugated polyelectrolytes supported on colloids Langmuir, 24:11053-11062 (2008).
Chile Patent Application No. 3274-2015 Office Action dated Jun. 20, 2017.
U.S. Appl. No. 14/889,818 Office Action dated Jun. 9, 2017.
U.S. Appl. No. 14/889,818 Office Action dated Sep. 27, 2016.
U.S. Appl. No. 13/990,755 Office Action dated Apr. 5, 2018.
U.S. Appl. No. 15/372,299 Office Action dated Apr. 23, 2018.
Usacheva et al., Interaction of the photobactericides methylene blue and toluidine blue with a fluorophore in Pseudomonas aeruginosa cells. Lasers in Surgery and Medicine, 40:55-61, 2008.
Varani et al., Human skin in organ culture and human skin cells (keratinocytes and fibroblasts) in monolayer culture for assessment of chemically induced skin damage. Toxicol Pathol., 35(5):693-701, 2007.
Vengerovsky, A.I., Pharmaceutical incompatibility. Bulletin of Siberian Medicine, 3:12 pages, 2003. http.7lold.ssmu.ru/bull/03/3/1684.pdf.
Wainwright. Photodynamic antimicrobial chemotherapy (PACT). Journal of Antimicrobial Chemotherapy, 42:13-28, 1998.
Wainwright et al., The Use of new methylene blue in Pseudomonas aeruginosa biofilm destruction. Biofueling, 18:247-249, 2002. (Abstract only).
Walker M, Bowler P, Cochrane C. In vitro studies to show sequestration of matrix metalloprotienases by silver-containing wound care products. Ostomy Wound Manage. 2007; 53: 18-25.
Walker M, Metcalf D, Parsons D, Bowler P. A real-life clinical evaluation of a next-generation antimicrobial dressing on acute and chronic wounds. J Wound Care. 2015; 24: 11-22.
Webb R. A chronic case of confusion. J of Wound Care. 2017; 26: 421.
Welsby S. The Spectrum Activity of AQUACEL Ag+ with Strengthening Fibre Ribbon using an in Vitro Corrected Zone of Inhibition Assay. 2015. ConvaTec data on file.
White, “An historical overview of the use of silver in wound management,” Actisorb Silver 220, The Silver Supplement Part Two: Clinical Evidence, 6 (Supp. Pt. 2): 6 pages (2001).
Wilkinson H, Stephenson C, Hardman M. Comparing the effectiveness of polymer debriding devices using a porcine wound biofilm model. Adv Wound Care. 2016; 5: 475-85.
Wirtanen, G. et al., Performance Evaluation of disinfectant Formulations Using Poloxamer-hydrogel Biofilm-constructs, Journal of Applied Microbiology, 1998, 85:965-971.
Wolcott R. Biofilms cause chronic infections. J of Wound Care. 2017; 26: 423-5.
Wolcott R. Disrupting the biofilm matrix improves wound healing outcomes. J Wound Care. 2015; 24: 366-71.
Wolcott R, Rhoads D. A study of biofilm-based wound management in subjects with critical limb ischemia. J Wound Care. 2008; 17: 145-55.
Wolcott R, Sanford N, Gabrilska R, Oates J, Wilkinson J, Rumbaugh K. Microbiota is a primary cause of pathogenesis of chronic wounds. J Wound Care. 2016; 25: Sup10: S33-S43.
Wood et al., Erythrosine is a potential photosensitizer for the photodynamic therapy of oral plaque biofilms. Journal of Antimicrobial Chemotherapy, 57:680-684, 2006.
Zölß C, Cech JD. Efficacy of a new multifunctional surfactant-based biomaterial dressing with 1% silver sulphadiazine in chronic wounds. Int Wound J. 2016; 13: 738-43. doi: 10.1111/iwj.12361.
Birttleness, Definition of Brittleness at Dictionary.com, https://www.dictionary.com/browse/brittleness, retrieved Sep. 25, 2019.
Sawhney, APS et al., Advent of Greige Cotton Non-Wovens Made using a Hydro-Entanglement Process, Textile Research Journal, vol. 80 (15), p. 1540-1549, 2010.
Australian Examination Report, Australian Patent Office, Australian Patent Application No. 2018204434, dated May 2, 2019, 4 pages.
Canadian Office Action, Canadian Intellectual Property Office, Canadian Patent Application No. 2,895,896, dated Dec. 13, 2019, 4 pages.
Japanese Office Action, Japan Patent Office, Japanese Patent Application No. 2018-223751, dated Nov. 5, 2019, 5 pages.
Related Publications (1)
Number Date Country
20200299865 A1 Sep 2020 US
Continuations (1)
Number Date Country
Parent 14654498 US
Child 16806255 US